Mavacamten single box market price analysis

Mavacamten is an innovative cardiac myosin inhibitor targeting hypertrophic cardiomyopathy (HCM). The drug was approved for marketing overseas in 2022 and entered the Chinese market in 2024. It was included in the medical insurance directory and used to treat patients with New York Heart Association (NYHA) grade II to III obstructive hypertrophic cardiomyopathy. Because it is the first oral small molecule drug that directly acts on the myocardial contraction mechanism, it has attracted widespread attention in the global cardiovascular field after its launch.

In China, the specifications of Mavacitai are usually packaged in four dosages: 2.5 mg, 5 mg, 10 mg and 15 mg. The common formats are 2.5 mg × 14 capsules × 2 plates or 5 mg × 14 capsules × 2 plates. Although the drug has been included in medical insurance, its price is still affected by many factors, including import channels, supply areas, hospital procurement policies and medical insurance reimbursement ratios. At present, the public prices at the domestic retail end have not been completely unified, and there are certain gaps between different regions. Overall, the out-of-pocket cost of patients after medical insurance reimbursement is significantly lower than the original price, giving more patients with cardiomyopathy the opportunity to receive standardized treatment.

In the international market, the price of the American version of Mavakatai is relatively high, with each boxThe 2.5mg specification is equivalent to about 60,000 yuan, while the price of the 5mg version in the European Union is about 20,000 yuan. The price difference is mainly due to the medical insurance system, pricing policy and exchange rate fluctuations. As global market demand grows, generic versions have emerged in some countries and regions. Their active ingredients are the same as the original drugs, but due to differences in patent protection and quality supervision, the price is lower, usually around RMB 1,500.

Overall, the market price of Mavakatai is still in the dynamic adjustment stage. Due to high R&D investment and brand recognition, the price of original drugs will remain high in the short term; while the gradual emergence of generic drugs is expected to promote a gradual balance in the price system and benefit patients who take long-term medication.

Reference materials:https://bnf.nice.org.uk/drugs/mavacamten/